Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H23NO2 |
Molecular Weight | 273.37 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)[C@@]1(CCC=C[C@H]1N(C)C)C2=CC=CC=C2
InChI
InChIKey=WDEFBBTXULIOBB-WBVHZDCISA-N
InChI=1S/C17H23NO2/c1-4-20-16(19)17(14-10-6-5-7-11-14)13-9-8-12-15(17)18(2)3/h5-8,10-12,15H,4,9,13H2,1-3H3/t15-,17+/m1/s1
Molecular Formula | C17H23NO2 |
Molecular Weight | 273.37 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 14:59:30 UTC 2023
by
admin
on
Fri Dec 15 14:59:30 UTC 2023
|
Record UNII |
GY33N31E9Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
||
|
WHO-VATC |
QN02AX01
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
||
|
NCI_THESAURUS |
C241
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
||
|
DEA NO. |
9750
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
||
|
WHO-ATC |
N02AX01
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2663
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | |||
|
DB13787
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | |||
|
D013993
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | |||
|
243-774-7
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
ALTERNATIVE | |||
|
10597
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | RxNorm | ||
|
GY33N31E9Y
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | |||
|
m10864
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | Merck Index | ||
|
257-522-9
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | |||
|
100000082696
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | |||
|
TILIDINE
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | |||
|
20380-58-9
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
SUPERSEDED | |||
|
51931-66-9
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | |||
|
C152628
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | |||
|
SUB11051MIG
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | |||
|
2510
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | |||
|
77823
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | |||
|
CHEMBL2220384
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY | |||
|
30131
Created by
admin on Fri Dec 15 14:59:30 UTC 2023 , Edited by admin on Fri Dec 15 14:59:30 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
TARGET->WEAK AGONIST |
Inhibition of forskolin-induced cAMP accumulation
IC50
|
||
|
ACTIVE ENANTIOMER->RACEMATE |
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
||
|
METABOLITE ACTIVE -> PRODRUG |
After oral intake tilidine is completely absorbed and rapidly metabolised to nortilidine, bisnortilidine. 100 fold more active than Tilidine.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|